Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 10 institutions in 4 countries.
Kaoru MurakamiSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-4226-3867
Hideki FuruyaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-9536-8662
Kanani HokutanClinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Steve GoodisonDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Ian PaganoPopulation Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.ORCID 0000-0002-6248-0113
Runpu ChenDepartment of Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY 14260, USA.
Cheng-Huang ShenDepartment of Urology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600, Taiwan.ORCID 0000-0003-0058-5128
Michael W Y ChanDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.ORCID 0000-0003-1431-322X
Chi Fai NgSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-1723-9646
Takashi KobayashiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.ORCID 0000-0003-1069-2816
Osamu OgawaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
Makito MiyakeDepartment of Urology, Nara Medical University, Nara 6348522, Japan.ORCID 0000-0001-9503-7356
Mark ThornquistFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Yoshiko ShimizuClinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Kazukuni HayashiClinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Zhangwei WangPopulation Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Herbert YuPopulation Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Charles J RosserSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-6052-4223
University of Hawaiʻi at Mānoa · USCedars-Sinai Medical Center · USKyoto University · JPChia-Yi Christian Hospital · TWChinese University of Hong Kong · HKFred Hutch Cancer Center · USMayo Clinic in Florida · USNara Medical University · JPNational Chung Cheng University · TWUniversity at Buffalo, State University of New York · US
Funding
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
VALIDATION OF A MULTIPLEXED ASSAY FOR BLADDER CANCER DIAGNOSISR01CA198887 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI ROSSER, CHARLES J · 2016 to 2025
$6.8M
Training in Cardiovascular Research at the University of HawaiiT32HL115505 · NHLBI · UNIVERSITY OF HAWAII AT MANOA · PI Michelle D Tallquist · 2012 to 2026
$3.8M
APPLICATION OF A MULTIPLEXED IMMUNOASSAY FOR THE DETECTION OF BLADDER CANCERUH3CA271377 · NCI · CEDARS-SINAI MEDICAL CENTER · PI ROSSER, CHARLES J · 2022 to 2024
$1.2M
Humanized anti-CXCL1 antibody for bladder cancer therapeuticsR21CA263230 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FURUYA, HIDEKI · 2021 to 2022
purposeBladder cancer (BCa) is one of the most common cancer types worldwide and is characterized by a high rate of recurrence. In previous studies, we and others have described the functional influence of plasminogen activator inhibitor-1 (PAI1) in bladder cancer development. While polymorphisms in
methodsIn this study, we evaluated the mutational status of PAI1 in a series of independent cohorts, comprised of a total of 660 subjects.
resultsSequencing analyses identified two clinically relevant 3' untranslated region (UTR) single nucleotide polymorphisms (SNPs) in
conclusionFurther investigation of the prevalence and potential downstream influence of these SNPs in bladder cancer is warranted.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. · full record | OpenQuestion